Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis.
D000328:Adult; D000368:Aged; D000077944:Alefacept; D001691:Biological Therapy; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D018570:Risk Assessment; D012720:Severity of Illness Index; D013601:T-Lymphocytes / Q000187:drug effects; D016896:Treatment Outcome
D011993:Recombinant Fusion Proteins; D000077944:Alefacept